SGC Open Notebookers support DIPG drug discovery by sharing their research on ALK2 in real-time In January 2018, a group of post-doctoral fellows at the Structural Genomics Consortium (SGC) undertook the bold task of sharing their real-time and unpolished experimental results through open lab notebooks online in a mission to facilitate collaboration and transparency [...]
Editorial: Research community ready for Open Source Drug Discovery In an Editorial to the Canadian Science Policy Centre, Drs. Aled Edwards and Aidan Hollis describe the need for Open Source Drug Discovery to address the inefficiencies in developing new drugs and the resulting exorbitant prices of new medicines. The support for M4K [...]
Listen to a recording of the February Monthly Scientific Meeting Listen to M4K Pharma's Scientific Update Meeting from February 6th, 2018 where our scientists and collaborators discuss the latest progress in our Medicines4Kids project for a deadly children's brain cancer called DIPG. Everyone is invited to hear first-hand how we are developing [...]
OICR's Cancer Therapeutics Innovation Pipeline initiative funds M4K's ALK2 program for DIPG as part of the inaugural set of projects The Ontario Institute for Cancer Research (OICR) announced its Cancer Therapeutics Innovation Pipeline (CTIP) initiative and the first 10 projects selected for the inaugural round of funding. CTIP will support the [...]
Making medicine, not money: How one U of T researcher's startup is rethinking Big Pharma's business model M4K Pharma's first target is a rare childhood brain cancer that's just as deadly as it was 50 years ago From U of T News (November 3, 2017) The latest medical innovation to [...]
